This study is looking at ways to improve electroconvulsive therapy (ECT) for people with depression. It compares two approaches to ECT: one uses a traditional device with a fixed electrical amplitude (strength), and the other uses a special adapter (Soterix Medical Incorporated 4x1 adapter) to allow for individualized amplitude. The goal is to see if adjusting the amplitude for each person can lead to better results for depression and cognitive (thinking) abilities. You might be able to join if you are 50 or older, have major depressive disorder or bipolar II, and are scheduled for ECT with right unilateral electrode placement. The study will measure changes in your depression symptoms and verbal fluency (how easily you can think of words) after 4 weeks to see if the individualized approach is more effective.

Study design

This is a randomized controlled trial involving 50 participants, split into two groups to compare individualized amplitude ECT with traditional fixed amplitude ECT.

What's involved

You will receive baseline imaging, clinical assessments (like the Inventory of Depressive Symptomatology), and neuropsychological assessments (like the Delis Kaplan Executive Function System Verbal Fluency) 24 to 48 hours before your first ECT session.

Compensation

Not stated in the trial record.

Follow-up

Your depression symptoms and verbal fluency will be measured at 4 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.